Log in or Sign up for Free to view tailored content for your specialty!
Therapeutics/Diagnostics News

Q&A: ‘Everyone benefits’ from noninvasive, individualized monitoring in pediatric IBD
SAN FRANCISCO — Noninvasive monitoring methods, such as enterography and ultrasound, are becoming increasingly recognized as essential tools in the management of pediatric patients with inflammatory bowel disease, according to presenters.
Stool DNA testing ‘can be performed safely’ regardless of anticoagulant, antiplatelet use

Oral anticoagulant or antiplatelet medication use had no substantial effect on the accuracy of multitarget stool DNA testing for colorectal cancer, according to a study published in Gastro Hep Advances.
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory bowel disease, Lilly reported.
Log in or Sign up for Free to view tailored content for your specialty!
Prucalopride still effective in CIC despite older age, unhealthy BMI or renal impairment

Prucalopride was safe and effective in increasing the frequency of complete spontaneous bowel movements in patients with chronic idiopathic constipation, regardless of age, BMI or renal function, according to data.
Improved physician ADR from a baseline of less than 26% linked to lower CRC risk

Improvement in adenoma detection rate among physicians with a baseline rate of less than 26% was significantly associated with decreased patient risk for colorectal cancer, according to results of an observational study conducted in Poland.
Can uptick in noninvasive CRC screening tests compete with standard colonoscopy?

Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially the first FDA-approved blood test. However, experts are unsure whether these will be as effective as colonoscopy.
Biosimilar boom set to expand treatment landscape for IBD, inflammatory diseases in 2025

The expansion of safe and effective FDA-approved biosimilars for inflammatory bowel disease set to launch in early 2025 may improve access to care, with the potential to reduce health care costs and revolutionize the treatment landscape.
FDA approves Ionis’ Tryngolza as first treatment for familial chylomicronemia syndrome

The FDA approved Tryngolza for the treatment of adults with familial chylomicronemia syndrome when used in combination with an appropriate low-fat diet, according to an Ionis Pharmaceutical press release.
AGA updates living guideline on pharmacological management of moderate to severe UC

In light of a “significant expansion in the therapeutic armamentarium” for moderate to severe ulcerative colitis, the AGA has released an updated living clinical practice guideline of patient-centered pharmacological interventions.
Concomitant use of common medications does not significantly affect UC induction therapy

Baseline concomitant exposure to commonly used medications, such as corticosteroids and 5-aminosalicylates, did not significantly affect clinical and endoscopic outcomes during induction therapy in ulcerative colitis, data analysis showed.
-
Headline News
Veterinarians had undetected bird flu infections, but such cases are rare, CDC says
February 19, 20252 min read -
Headline News
Semaglutide may raise risk for form of optic neuropathy in adults with type 2 diabetes
February 20, 20253 min read -
Headline News
CDC disease detectives ‘remain in their positions,’ agency says
February 20, 20253 min read
-
Headline News
Veterinarians had undetected bird flu infections, but such cases are rare, CDC says
February 19, 20252 min read -
Headline News
Semaglutide may raise risk for form of optic neuropathy in adults with type 2 diabetes
February 20, 20253 min read -
Headline News
CDC disease detectives ‘remain in their positions,’ agency says
February 20, 20253 min read